share_log
Breakings ·  Jun 1 19:00
Cullinan Therapeutics Announces Positive Initial Data From Pivotal Phase 2B Rezilient1 Study of Zipalertinib
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment